NO20024177L - Pharmaceutical preparations containing azetidine derivatives, the new azetidine derivatives and their preparation - Google Patents

Pharmaceutical preparations containing azetidine derivatives, the new azetidine derivatives and their preparation

Info

Publication number
NO20024177L
NO20024177L NO20024177A NO20024177A NO20024177L NO 20024177 L NO20024177 L NO 20024177L NO 20024177 A NO20024177 A NO 20024177A NO 20024177 A NO20024177 A NO 20024177A NO 20024177 L NO20024177 L NO 20024177L
Authority
NO
Norway
Prior art keywords
azetidine derivatives
preparation
pharmaceutical preparations
preparations containing
new
Prior art date
Application number
NO20024177A
Other languages
Norwegian (no)
Other versions
NO20024177D0 (en
NO324524B1 (en
Inventor
Daniel Achard
Herve Bouchard
Jean Bouquerel
Bruno Filoche
Serge Grisoni
Augustin Hittinger
Michael Myers
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20024177D0 publication Critical patent/NO20024177D0/en
Publication of NO20024177L publication Critical patent/NO20024177L/en
Publication of NO324524B1 publication Critical patent/NO324524B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)

Abstract

The invention concerns pharmaceutical compositions containing as active principle a compound of formula (I) wherein: R1 represents a -N(R4)R5, -N(R4)-CO-R5, -N(R4)-SO2R6 radical or one of its pharmaceutically acceptable salts, the novel derivatives of formula (I), their pharmaceutically acceptable salts and their preparation.
NO20024177A 2000-03-03 2002-09-02 Pharmaceutical preparations containing azetidine derivatives, the new azetidine derivatives and their preparation NO324524B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002776A FR2805817B1 (en) 2000-03-03 2000-03-03 PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION
PCT/FR2001/000602 WO2001064634A1 (en) 2000-03-03 2001-03-01 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof

Publications (3)

Publication Number Publication Date
NO20024177D0 NO20024177D0 (en) 2002-09-02
NO20024177L true NO20024177L (en) 2002-10-29
NO324524B1 NO324524B1 (en) 2007-11-12

Family

ID=8847706

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024177A NO324524B1 (en) 2000-03-03 2002-09-02 Pharmaceutical preparations containing azetidine derivatives, the new azetidine derivatives and their preparation

Country Status (36)

Country Link
EP (1) EP1263722B1 (en)
JP (1) JP4883867B2 (en)
KR (1) KR100819572B1 (en)
CN (1) CN100386314C (en)
AT (1) ATE478841T1 (en)
AU (1) AU780880B2 (en)
BG (1) BG66001B1 (en)
BR (1) BR0108893B1 (en)
CA (1) CA2400141C (en)
CY (1) CY1111071T1 (en)
CZ (1) CZ301254B6 (en)
DE (1) DE60142891D1 (en)
DK (1) DK1263722T3 (en)
DZ (1) DZ3312A1 (en)
EA (1) EA007109B1 (en)
EE (1) EE05103B1 (en)
ES (1) ES2351276T3 (en)
FR (1) FR2805817B1 (en)
HR (1) HRP20020712B1 (en)
HU (1) HUP0400636A3 (en)
IL (2) IL151321A0 (en)
MA (1) MA26880A1 (en)
ME (1) MEP9509A (en)
MX (1) MXPA02008349A (en)
NO (1) NO324524B1 (en)
NZ (1) NZ521077A (en)
OA (1) OA12222A (en)
PL (1) PL208021B1 (en)
PT (1) PT1263722E (en)
SI (1) SI1263722T1 (en)
SK (1) SK287445B6 (en)
TW (1) TWI304399B (en)
UA (1) UA73554C2 (en)
WO (1) WO2001064634A1 (en)
YU (1) YU66002A (en)
ZA (1) ZA200206912B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022579A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
FR2814678B1 (en) * 2000-10-04 2002-12-20 Aventis Pharma Sa COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
FR2833842B1 (en) * 2001-12-21 2004-02-13 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
RU2304580C2 (en) 2002-07-29 2007-08-20 Ф.Хоффманн-Ля Рош Аг Novel benzodioxols
PL378244A1 (en) 2003-01-02 2006-03-20 F. Hoffmann-La Roche Ag Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists
WO2004060870A1 (en) 2003-01-02 2004-07-22 F. Hoffmann-La Roche Ag Novel cb 1 receptour inverse agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1601665A2 (en) * 2003-03-07 2005-12-07 Glaxo Group Limited Urea derivatives
JP2006525297A (en) * 2003-05-01 2006-11-09 ヴァーナリス リサーチ リミテッド Use of azetidine carboxamide derivatives in therapy
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
ES2303077T3 (en) 2003-06-20 2008-08-01 F. Hoffmann-La Roche Ag 2-AMINOBENZOTIAZOLES AS INVESTED AGONISTS OF THE CB1 RECEIVER.
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
CN100509808C (en) 2003-12-08 2009-07-08 霍夫曼-拉罗奇有限公司 Novel thiazole derivates
EP1716132B1 (en) 2004-01-28 2010-08-25 F. Hoffmann-La Roche AG Spiro-benzodioxoles and their use as cb1 antagonists
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
JP2007536298A (en) 2004-05-10 2007-12-13 エフ．ホフマン−ラ　ロシュ　アーゲー Pyrrole or imidazole amide for the treatment of obesity
FR2876688B1 (en) * 2004-10-14 2007-03-16 Aventis Pharma Sa NEW PRODUCT, PROCESS AND INTERMEDIATES FOR PREPARING AZETIDINE DERIVATIVES
FR2876689B1 (en) * 2004-10-14 2008-02-22 Aventis Pharma Sa NOVEL PROCESS AND INTERMEDIATES FOR PREPARING N- (1-BENZHYDRYL-AZETIDIN-3-YL) -N-PHENYL-METHYLSULFONAMIDE DERIVATIVES
ES2309812T3 (en) 2004-10-27 2008-12-16 F. Hoffmann-La Roche Ag NEW DERIVATIVES OF INDOL OR BENZIMIDAZOL.
EP1812418B1 (en) 2004-11-09 2010-10-27 F. Hoffmann-La Roche AG Dibenzosuberone derivatives
DE602006007563D1 (en) 2005-04-06 2009-08-13 Hoffmann La Roche AGONIST
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
CA2619770A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
JP4371164B2 (en) 2005-11-10 2009-11-25 萬有製薬株式会社 Aza-substituted spiro derivatives
AR058199A1 (en) * 2005-11-28 2008-01-23 Merck & Co Inc DERIVATIVES OF 3- RENTED ALQUILAZETIDINA WITH HETEROCICLOS
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (en) 2006-09-28 2010-01-28 萬有製薬株式会社 Diaryl ketimine derivatives
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
FR2925050B1 (en) * 2007-12-14 2010-01-08 Sanofi Aventis NEW PROCESS FOR THE PREPARATION OF AZETIDINE DERIVATIVES
EA019315B1 (en) * 2007-12-18 2014-02-28 Санофи-Авентис Azetidine derivatives, their preparation and their application in therapy
FR2930941B1 (en) * 2008-05-06 2010-06-18 Sanofi Aventis AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2928149B1 (en) 2008-02-29 2011-01-14 Sanofi Aventis AZETIDINE-DERIVED COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
JPWO2009154132A1 (en) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 Spirodiamine-diarylketoxime derivatives
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
FR2934996B1 (en) * 2008-08-14 2010-08-27 Sanofi Aventis AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
FR2934995B1 (en) * 2008-08-14 2010-08-27 Sanofi Aventis POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5635991B2 (en) 2008-10-30 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Isonicotinamide orexin receptor antagonist
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
FR2946650B1 (en) * 2009-06-16 2011-08-19 Sanofi Aventis ESTERS DERIVED FROM AZETIDINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS.
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
JP2013520502A (en) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション Novel cyclic benzimidazole derivatives that are useful anti-diabetic drugs
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
MX348131B (en) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents.
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
MX2015001500A (en) 2012-08-02 2015-04-08 Merck Sharp & Dohme Antidiabetic tricyclic compounds.
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
RS65632B1 (en) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
TWI767945B (en) 2016-10-14 2022-06-21 義大利商Ｔｅｓ製藥（股份）責任有限公司 INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
TW202045476A (en) 2019-02-13 2020-12-16 美商默沙東藥廠 5-alkyl pyrrolidine orexin receptor agonists
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CN116249697A (en) 2020-08-18 2023-06-09 默沙东有限责任公司 Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
FR2649100B1 (en) * 1989-06-29 1994-03-04 Laboratorios Dr Esteve Sa NOVEL AZETIDINES, THEIR PREPARATION AND THEIR APPLICATION AS INTERMEDIATES FOR THE PREPARATION OF COMPOUNDS WITH ANTIMICROBIAL ACTIVITY
US5556861A (en) * 1991-10-01 1996-09-17 Laboratoire Roger Bellon 1,8 benzonaphthyridine derivatives and antimicrobial compositions
CA2166975C (en) * 1993-07-16 2005-04-05 Mark G. Bock Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US6022868A (en) * 1995-06-29 2000-02-08 Novo Nordisk Als Substituted azacyclic or azabicyclic compounds
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines

Also Published As

Publication number Publication date
IL151321A (en) 2008-11-03
SK287445B6 (en) 2010-10-07
AU3752701A (en) 2001-09-12
EP1263722A1 (en) 2002-12-11
HUP0400636A2 (en) 2004-06-28
ES2351276T3 (en) 2011-02-02
NO20024177D0 (en) 2002-09-02
BR0108893A (en) 2002-11-05
PL365046A1 (en) 2004-12-27
JP4883867B2 (en) 2012-02-22
AU780880B2 (en) 2005-04-21
BG107058A (en) 2003-07-31
PL208021B1 (en) 2011-03-31
UA73554C2 (en) 2005-08-15
EP1263722B1 (en) 2010-08-25
KR20020075469A (en) 2002-10-04
CN100386314C (en) 2008-05-07
ZA200206912B (en) 2003-11-03
EA200200938A1 (en) 2003-02-27
CZ301254B6 (en) 2009-12-23
CN1418192A (en) 2003-05-14
ATE478841T1 (en) 2010-09-15
OA12222A (en) 2006-05-10
HRP20020712B1 (en) 2012-11-30
DE60142891D1 (en) 2010-10-07
SI1263722T1 (en) 2010-12-31
CY1111071T1 (en) 2015-06-11
MXPA02008349A (en) 2002-12-13
NZ521077A (en) 2004-09-24
EE05103B1 (en) 2008-12-15
DK1263722T3 (en) 2011-01-03
EE200200485A (en) 2004-02-16
HRP20020712A2 (en) 2005-10-31
YU66002A (en) 2005-09-19
DZ3312A1 (en) 2001-09-07
TWI304399B (en) 2008-12-21
BG66001B1 (en) 2010-09-30
MA26880A1 (en) 2004-12-20
WO2001064634A1 (en) 2001-09-07
IL151321A0 (en) 2003-04-10
SK12432002A3 (en) 2003-06-03
CA2400141C (en) 2012-02-21
JP2003525270A (en) 2003-08-26
PT1263722E (en) 2010-11-23
KR100819572B1 (en) 2008-04-04
FR2805817B1 (en) 2002-04-26
NO324524B1 (en) 2007-11-12
FR2805817A1 (en) 2001-09-07
HUP0400636A3 (en) 2004-09-28
CA2400141A1 (en) 2001-09-07
BR0108893B1 (en) 2013-06-04
EA007109B1 (en) 2006-06-30
MEP9509A (en) 2011-12-20

Similar Documents

Publication Publication Date Title
NO20024177L (en) Pharmaceutical preparations containing azetidine derivatives, the new azetidine derivatives and their preparation
NO20034660L (en) Spiropyrazole compounds, pharmaceutical compositions comprising such a compound, and the use of the compounds for the preparation of pharmaceutical preparations
NO20033732L (en) N-substituted non-aryl heterocyclic NMDA / NR2B antagonists, and pharmaceutical compositions comprising such compounds.
NO20070224L (en) 2-urea-4-phenylthiazole derivatives, preparation and therapeutic use thereof
NO20014485L (en) New compounds and compositions as protease inhibitors
DK2314582T3 (en) Heterocyclic compounds as antiviral agents
YU65802A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
NO20050088L (en) Cationically substituted diphenylazofidinones, processes for their preparation, medicaments containing said compounds, and use thereof
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
DE602004008098D1 (en) SUBSTITUTED 2H-Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRAZINE AS GSK-3 INHIBITORS
MXPA02012033A (en) 2-aminocarbonyl-9h-purine derivatives.
NO20024176D0 (en) Pharmaceutical preparations containing 3-amino-azetidine derivatives, the novel derivatives and their preparation
NO20021859D0 (en) New digosaccharides, their preparation as well as pharmaceutical preparations
MXPA02003977A (en) INHIBITORS OF agr;L.
NO20040881L (en) Oral antidiabetic agents.
MXPA05011176A (en) Carboxamide derivatives as anti-diabetic agents.
NO20001781L (en) 3-amino-3-arylpropane-1 and the like derivatives, their preparation and use
DE60114640D1 (en) Antithrombosemittel
ATE253359T1 (en) ANTITHRBOTIC AGENTS
EA200201024A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING OLIGOSACCHARIDES AND THEIR RECEIVING
DK1411956T3 (en) Use of oversulfated polysaccharides as inhibitors of HIV
DE60008430D1 (en) ANTITHROMBOTIC EFFECT COMPOUNDS
AP2001002179A0 (en) 2-Aminocarbonyl-9h-purine derivatives.
EA200100953A1 (en) L-ARABINO-DISAHARIDES ANTHRACYCLINES, METHODS FOR THEIR RECEPTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees